Navigation Links
ChanTest to Highlight Expanded Ion Channel Testing Services for Preclinical Safety at ToxExpo, Including the World's Largest Catalog of Validated Ion Channels, Booth 2504
Date:3/11/2008

CLEVELAND, March 11 /PRNewswire/ -- ChanTest, the leading provider of ion channel testing services for drug discovery and development customers, will feature the latest in its expanding line of services in booth 2504 at the Society of Toxicology conference March 17-20, in Seattle, Washington. New FDA Critical Path safety profiling tools include the Cardiac Channel Panel(TM) and Brain Channel Panel(TM), which ChanTest designed to complement the FDA and ICH S7A safety guidance, as well as the Pain/Inflammation and Epilepsy Channel Panels for profiling by therapeutic target. ChanTest has validated the panels against the "gold standard" manual patch clamp to ensure that results from early screens will correlate during the GLP studies that are required for IND submission.

According to Dr. Arthur (Buzz) Brown, founder and CEO of ChanTest, "At ChanTest, we've designed our comprehensive range of ion channel assays, follow-up models, and consultation services to give customers the early answers they need to identify the most-promising drug targets, and eliminate those that could be harmful - before they invest millions on clinical trials. ChanTest is the most experienced ion channel services company in the world. Our scientific team is dedicated to providing the individual attention customers need to move their project successfully through the IND process. We work closely with customers worldwide to design a testing program that meets their drug discovery, safety, regulatory, and budgetary goals. Then, we use the latest screening techniques and proprietary assays to deliver fast, accurate, and reliable results. We specialize in ion channel screening. Customers count on ChanTest because we don't just deliver raw data - our ion channel experts tell customers what the results mean."

ChanTest scientists were the first to prove hERG as the target for adverse cardiac events linked to non-cardiac drugs: Seldane (terfenadine), Propulsid (cisapride), and Nizoral (ketoconazole), and ChanTest pioneered the development of functional, cell-based ion channel testing as a means to predict cardiac side effects produced by non-cardiac drugs. Such testing is now a standard component of regulatory submissions prior to the approval of drugs for use in humans. ChanTest is committed to innovation, and is leading the next major advance in ion channel research and services with a $10 million program to develop the world's most extensive library or catalog of ion channels. ChanTest's expert electrophysiologists fully validate the ion channels for interrogation with functional, pharmacological, and biochemical assays.

About ChanTest

The preeminent ion channel services company, ChanTest serves its drug discovery and development customers with GLP safety and automated screening assays using its library of ion channel-expressing cell lines - the most comprehensive in the world. Since its inception in 1998, ChanTest has tested more than 12,000 compounds for more than 250 global pharmaceutical and biotech companies - helping them to achieve their drug safety and discovery goals. ChanTest works in partnership with customers to speed the drug-development process, save time and money, and ultimately - to help make better, safer drugs. Because of ChanTest's seminal role in this field, along with the company's uncompromising commitment to quality, ChanTest was named "most trusted fee-for-service provider" for ion channel screening in the HTStec Ion Channel Trends Survey for two years in a row. ChanTest is based in Cleveland, Ohio. For more information, please visit http://www.chantest.com.


'/>"/>
SOURCE ChanTest
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Helix BioPharma reports Q2 2008 highlights, financial results
2. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
3. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
4. MEDEA+ Noblanc award highlights improvements in microelectronics
5. National Nanotechnology Initiative releases its fiscal year 2009 budget and highlights
6. Coalition for a Competitive Pharmaceutical Market Launches New Print Ad Campaign Highlighting Need for Meaningful Biogenerics Legislation
7. CyberKnife Users Meeting Highlights Major Clinical Data Milestones and Emerging Trends
8. BioTrends Releases Fourth Annual Nephrology TreatmentTrends Publication Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
9. Oncothyreon highlights corporate and clinical objectives for 2008
10. CryoCor to Highlight Products at 13th Annual International Boston Atrial Fibrillation Symposium
11. Highlights of Economic and Business Growth in the Tampa Bay Region
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2016)... ... May 19, 2016 , ... KCAS Bioanalytical and Biomarker Services, ... Director, Large Molecule & Biomarker Bioanalysis. , Dr. Siddiqui has more than 15 ... for preclinical and clinical safety programs. “We’ve seen significant demand for, and we ...
(Date:5/18/2016)... ... 18, 2016 , ... Tech Coast Angels (TCA) today announced that ... at the annual ACA Summit last week in Philadelphia. , The award ... member angel groups. It is the highest honor available for an early-stage company to ...
(Date:5/18/2016)... ... May 18, 2016 , ... STACS DNA Inc., the sample ... track and report sexual assault kit processing to help them save time and reduce ... escalates for kits to be processed and victims informed of results. Due to a ...
(Date:5/18/2016)... ... 2016 , ... Ryan Benton was diagnosed with Duchenne Muscular Dystrophy (DMD) at ... early twenties. DMD is a relatively common progressive genetic disorder, which causes aggressive deterioration ... was critical. He met with the founder of the Stem Cell Institute ...
Breaking Biology Technology:
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
(Date:3/31/2016)... BOCA RATON, Florida , March 31, 2016 /PRNewswire/ ... LEGX ) ("LegacyXChange" or the "Company") ... presentation for potential users of its soon to be ... The video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also ... by the use of DNA technology to an industry ...
Breaking Biology News(10 mins):